{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:35:48Z","timestamp":1790937348355,"version":"4.1.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/bor.0b013e32835b1366","type":"journal-article","created":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T02:47:18Z","timestamp":1351651638000},"page":"56-64","source":"Crossref","is-referenced-by-count":140,"title":["Biologics-induced autoimmune diseases"],"prefix":"10.1097","volume":"25","author":[{"given":"Roberto","family":"Perez-Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"P\u00e9rez-de-Lis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ramos-Casals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MD.0b013e318190f170","article-title":"A systematic review of the off- label use of biological therapies in systemic autoimmune diseases.","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"R2-12-20210128","first-page":"188","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword Autoimmun R","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"ev"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-011-1924-x","article-title":"Chilblain lupus induced by TNF-a antagonists: a case report and literature review.","volume":"31","author":"SifuentesGiraldo","year":"2012","journal-title":"Clin Rheumatol"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ibd.21362","article-title":"Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF- antibody-treated patients with inflammatory bowel disease.","volume":"17","author":"Beigel","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1755-7682-5-7","article-title":"Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-a.","volume":"5","author":"Puertas-Abreu","year":"2012","journal-title":"Int Arch Med"},{"key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.amjmed.2011.09.010","article-title":"B-cell-depleting therapy in systemic lupus erythematosus.","volume":"125","author":"Ramos-Casals","year":"2012","journal-title":"Am J Med"},{"key":"R7-12-20210128","first-page":"183","article-title":"Paradoxical reactions to targeted biological treatments: a way to treat and trigger Acta Derm V","volume":"90","author":"Brunasso","year":"2010","journal-title":"enereol"},{"key":"R8-12-20210128","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jbspin.2011.07.001","article-title":"Antiphospholipid syndrome development after rituximab treatment.","volume":"79","author":"Faillace","year":"2012","journal-title":"Joint Bone Spine"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11926-008-0072-z","article-title":"Vasculitis induced by tumor necrosis factor-targeted therapies.","volume":"10","author":"Ramos-Casals","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"R10-12-20210128","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.mayocp.2012.04.011","article-title":"Vasculitis associated with tumor necrosis factor-a inhibitors.","volume":"87","author":"Sokumbi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"R11-12-20210128","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.crohns.2012.02.019","article-title":"Reversible Henoch-Schonleinpurpuracomplicating adalimumab therapy.","volume":"6","author":"Marques","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4292\/wjgpt.v1.i5.119","article-title":"Henoch-Schonleinpurpura complicating adalimumab therapy for Crohns disease.","volume":"1","author":"Rahman","year":"2010","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/RHU.0b013e31819bca9e","article-title":"Herpes zoster infection followed by Henoch-Schonleinpurpura in a girl receiving infliximab for ulcerative colitis.","volume":"15","author":"Nobile","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.rhu.0000239901.34561.5e","article-title":"Henoch-Schonleinpurpura after etanercept therapy for psoriasis.","volume":"12","author":"Lee","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1684\/ejd.2010.0977","article-title":"Henoch-Schonleinpurpura in a patient with rheumatoid arthritis receiving etanercept.","volume":"20","author":"Asahina","year":"2010","journal-title":"Eur J Dermatol"},{"key":"R16-12-20210128","first-page":"S106","article-title":"HenochSchonleinpurpura following etanercept treatment of rheumatoid arthritis.","volume":"24","author":"Duffy","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00296-011-1812-3","article-title":"Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis.","volume":"32","author":"Mendonca","year":"2012","journal-title":"Rheumatol Int"},{"key":"R18-12-20210128","first-page":"147","article-title":"Is there a link between the use of etanercept and Henoch-Schonleinpurpura Comment on: Henoch-Schonleinpurpura in a patient with the rheumatoid arthritis receiving etanercept (Eur J Dermatol 2010; 20: 521-522).","volume":"21","author":"Park","year":"2011","journal-title":"Eur J Dermatol"},{"key":"R19-12-20210128","first-page":"1785","article-title":"Onset of Wegeners granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event Rheumatology (Oxford","volume":"49","author":"Parekh","year":"2010","journal-title":")"},{"key":"R20-12-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/09273948.2011.623212","article-title":"Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature.","volume":"20","author":"Fonollosa","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/09273948.2011.623213","article-title":"Sarcoid-related uveitis occurring during adalimumab therapy.","volume":"20","author":"Seve","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2036.2012.05189.x","article-title":"Review article: nonmalignant haematological complications of antitumour necrosis factor alpha therapy.","volume":"36","author":"Bessissow","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000334805","article-title":"Eosinophilia during psoriasis treatment with TNF antagonists.","volume":"223","author":"Malisiewicz","year":"2011","journal-title":"Dermatology"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/rheumatology\/keg187","article-title":"Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab.","volume":"42","author":"Aouba","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R27-12-20210128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2169\/internalmedicine.51.5687","article-title":"Hemophagocyticlymphohistiocytosis in a rheumatoid arthritis patient treated with infliximab.","volume":"51","author":"Oda","year":"2012","journal-title":"Intern Med"},{"key":"R28-12-20210128","first-page":"449","article-title":"Tuberculosis associated with hemophagocytic syndrome complicated by treatment with infliximab.","volume":"48","author":"Numakura","year":"2010","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"R29-12-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11096-010-9369-x","article-title":"Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after treatment with infliximab.","volume":"32","author":"Troncoso Marino","year":"2010","journal-title":"Pharm World Sci"},{"key":"R30-12-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MPG.0b013e31816a30b9","article-title":"Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab.","volume":"47","author":"Francolla","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R31-12-20210128","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1086\/500262","article-title":"Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of antitumor necrosis factor-alpha antibody.","volume":"42","author":"Kohara","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R32-12-20210128","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2169\/internalmedicine.50.5430","article-title":"Etanercept-induced lupus accompanied by hemophagocytic syndrome.","volume":"50","author":"Araki","year":"2011","journal-title":"Intern Med"},{"key":"R33-12-20210128","first-page":"241","article-title":"Macrophage activation syndrome afteretanercepttreatment.","volume":"34","author":"Sandhu","year":"2007","journal-title":"J Rheumatol"},{"key":"R34-12-20210128","first-page":"401","article-title":"Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis.","volume":"30","author":"Ramanan","year":"2003","journal-title":"J Rheumatol"},{"key":"R35-12-20210128","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/acr.20001","article-title":"A 21-year-old man with Stills disease with fever, rash, and pancytopenia.","volume":"62","author":"Mehta","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R36-12-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","article-title":"BIOGEAS Study GroupMonoclonal antibody therapy-associated neurological disorders.","volume":"7","author":"Bosch","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"R37-12-20210128","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MAJ.0b013e31822b7bb8","article-title":"Neurological deficits during treatment with tumor necrosis factor-alpha antagonists.","volume":"342","author":"Nozaki","year":"2011","journal-title":"Am J Med Sci"},{"key":"R38-12-20210128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1684\/epd.2011.0439","article-title":"Infliximab-related seizures: a first case study.","volume":"13","author":"Brigo","year":"2011","journal-title":"Epileptic Disord"},{"key":"R39-12-20210128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy.","volume":"37","author":"Stubgen","year":"2008","journal-title":"Muscle Nerve"},{"key":"R40-12-20210128","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.amjmed.2010.11.028","article-title":"Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.","volume":"124","author":"Ramos-Casals","year":"2011","journal-title":"Am J Med"},{"key":"R41-12-20210128","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R42-12-20210128","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Noninfectious pulmonary toxicity of rituximab: a systematic review.","volume":"51","author":"Hadjinicolaou","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R43-12-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/RHU.0b013e31823ee5bf","article-title":"Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"18","author":"Arulkumaran","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"R44-12-20210128","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","article-title":"Noninfectious pulmonary complications of newer biological agents for rheumatic diseases: a systematic literature review.","volume":"50","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R46-12-20210128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","article-title":"New onset of uveitis during antitumor necrosis factor treatment for rheumatic diseases.","volume":"41","author":"Wendling","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R47-12-20210128","first-page":"2284","article-title":"Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect J R","volume":"38","author":"Wendling","year":"2011","journal-title":"heumatol"},{"key":"R48-12-20210128","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3899\/jrheum.100809","article-title":"Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.","volume":"38","author":"van Dijken","year":"2011","journal-title":"J Rheumatol"},{"key":"R50-12-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pharma.2011.06.005","article-title":"Ulcerative colitis: exceptional consequence after rituximab therapy.","volume":"69","author":"Sekkach","year":"2011","journal-title":"Ann Pharm Fr"},{"key":"R52-12-20210128","first-page":"e163","article-title":"Systemic adverse events following rituximab therapy in patients with Graves disease.","volume":"34","author":"ElFassi","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"R53-12-20210128","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/ibd.20215","article-title":"Exacerbation of ulcerative colitis after rituximab salvage therapy.","volume":"13","author":"Goetz","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R54-12-20210128","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1542\/peds.2009-3395","article-title":"Severe ulcerative colitis after rituximab therapy.","volume":"126","author":"Ardelean","year":"2010","journal-title":"Pediatrics"},{"key":"R55-12-20210128","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.30546","article-title":"Induction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathicspondylarthritis or ankylosing spondylitis and comorbid colitis.","volume":"63","author":"Fiehn","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R56-12-20210128","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","article-title":"Drug-induced autoimmune-like hepatitis.","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R57-12-20210128","doi-asserted-by":"crossref","first-page":"E149","DOI":"10.1002\/ibd.21880","article-title":"Infliximab-induced autoimmune hepatitis in Crohns disease treated with budesonide and mycophenolate.","volume":"17","author":"Subramaniam","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R58-12-20210128","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1007\/s10620-011-1748-1","article-title":"Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohns disease: the index case.","volume":"56","author":"Goldfeld","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R59-12-20210128","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00228-011-1191-4","article-title":"Autoimmune hepatitis induced by adalimumab with successful switch to abatacept.","volume":"68","author":"Grasland","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R60-12-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"R61-12-20210128","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2011.05.038","article-title":"Psoriasis and palmoplantarpustulosis associated with tumor necrosis factor- inhibitors: the Mayo Clinic experience, 1998 to 2010.","volume":"67","author":"Shmidt","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R62-12-20210128","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R63-12-20210128","first-page":"172","article-title":"The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended Arq G","volume":"49","author":"Denadai","year":"2012","journal-title":"astroenterol"},{"key":"R64-12-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving antitumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R65-12-20210128","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00296-011-1799-9","article-title":"Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment.","volume":"32","author":"Werner de Castro","year":"2012","journal-title":"Rheumatol Int"},{"key":"R66-12-20210128","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3899\/jrheum.111347","article-title":"Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry.","volume":"39","author":"Thomas","year":"2012","journal-title":"J Rheumatol"},{"key":"R67-12-20210128","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2340\/00015555-1042","article-title":"Psoriasiform drug eruption due to abatacept.","volume":"91","author":"Kato","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"R68-12-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-3083.2011.04042.x","article-title":"Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.","volume":"26","author":"Konsta","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R69-12-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D38M24603S","article-title":"A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept.","volume":"17","author":"Brigant","year":"2011","journal-title":"Dermatol Online J"},{"key":"R70-12-20210128","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1365-2133.2008.08470.x","article-title":"New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra.","volume":"158","author":"Gonzalez-Lopez","year":"2008","journal-title":"Br J Dermatol"},{"key":"R71-12-20210128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1600-0560.2012.01894.x","article-title":"Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.","volume":"39","author":"Hawryluk","year":"2012","journal-title":"J Cutan Pathol"},{"key":"R73-12-20210128","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.gastrohep.2011.04.003","article-title":"Ustekinumab in a patient with Crohns disease and anti-TNF--induced psoriasis.","volume":"34","author":"Sanso Sureda","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"R74-12-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1751-2980.2011.00522.x","article-title":"Antinuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.","volume":"12","author":"Verma","year":"2011","journal-title":"J Dig Dis"},{"key":"R75-12-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ibd.21370","article-title":"Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.","volume":"17","author":"Subramanian","year":"2011","journal-title":"Inflamm Bowel Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e32835b1366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T13:36:58Z","timestamp":1643549818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201301000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32835b1366","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}